Read by QxMD icon Read


Simon J Griffin, M Angelyn Bethel, Rury R Holman, Kamlesh Khunti, Nicholas Wareham, Gwen Brierley, Melanie Davies, Andrew Dymond, Rose Eichenberger, Philip Evans, Alastair Gray, Colin Greaves, Kyla Harrington, Graham Hitman, Greg Irving, Sarah Lessels, Ann Millward, John R Petrie, Martin Rutter, Mike Sampson, Naveed Sattar, Stephen Sharp
BACKGROUND: The treatment of people with diabetes with metformin can reduce cardiovascular disease (CVD) and may reduce the risk of cancer. However, it is unknown whether or not metformin can reduce the risk of these outcomes in people with elevated blood glucose levels below the threshold for diabetes [i.e. non-diabetic hyperglycaemia (NDH)]. OBJECTIVE: To assess the feasibility of the Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) and to estimate the key parameters to inform the design of the full trial...
April 2018: Health Technology Assessment: HTA
G Verstraete, W De Jaeghere, J Vercruysse, W Grymonpré, V Vanhoorne, F Stauffer, T De Beer, A Bezuijen, J P Remon, C Vervaet
Partially hydrolysed polyvinyl alcohol (PVA) was evaluated as a pelletisation aid for the production of pellets with a high acetaminophen and metformin hydrochloride concentration (>70%, w/w). Mixtures with varying drug concentration and PVA/microcrystalline cellulose (MCC) ratios were processed via extrusion-spheronisation, either after addition of PVA as a dry powder or as an aqueous solution. Finally, high drug- loaded metformin pellets were coated with a methacrylic acid copolymer (Eudragit™ NM 30D) and evaluated for their sustained release potency in vitro and in vivo...
January 30, 2017: International Journal of Pharmaceutics
Diane Farrar, Mark Simmonds, Susan Griffin, Ana Duarte, Debbie A Lawlor, Mark Sculpher, Lesley Fairley, Su Golder, Derek Tuffnell, Martin Bland, Fidelma Dunne, Donald Whitelaw, John Wright, Trevor A Sheldon
BACKGROUND: Gestational diabetes mellitus (GDM) is associated with a higher risk of important adverse outcomes. Practice varies and the best strategy for identifying and treating GDM is unclear. AIM: To estimate the clinical effectiveness and cost-effectiveness of strategies for identifying and treating women with GDM. METHODS: We analysed individual participant data (IPD) from birth cohorts and conducted systematic reviews to estimate the association of maternal glucose levels with adverse perinatal outcomes; GDM prevalence; maternal characteristics/risk factors for GDM; and the effectiveness and costs of treatments...
November 2016: Health Technology Assessment: HTA
Filip Haenen, Ben Gys, Tobie Gys, Thierry Lafullarde
BACKGROUND: Obesity is an increasing problem worldwide; patients who remain obese after non-surgical interventions are potential candidates for surgical intervention. Laparoscopic Roux-en-Y gastric bypass (RYGB) has proven its effects on excess weight loss and its positive effect on comorbidities and also, on reflux correction. CASE REPORT: Our patient, a 53-year-old male, with a BMI of 45 kg/m(2) and type 2 diabetes, underwent a Belsey-Mark IV procedure in another center because of a large hiatus hernia and intrathoracic stomach, in combination with gastroesophageal reflux disease (GERD)...
July 5, 2016: Acta Chirurgica Belgica
Cheng-Hung Lee, Kuo-Chun Hung, Shih-Jung Liu
No abstract text is available yet for this article.
September 10, 2015: Journal of Controlled Release: Official Journal of the Controlled Release Society
Sung Min Son, Hong-Joon Shin, Jayoung Byun, Sun Young Kook, Minho Moon, Yu Jin Chang, Inhee Mook-Jung
The evidence of strong pathological associations between type 2 diabetes and Alzheimer's disease (AD) has increased in recent years. Contrary to suggestions that anti-diabetes drugs may have potential for treating AD, we demonstrate here that the insulin sensitizing anti-diabetes drug metformin (Glucophage®) increased the generation of amyloid-β (Aβ), one of the major pathological hallmarks of AD, by promoting β- and γ-secretase-mediated cleavage of amyloid-β protein precursor (AβPP) in SH-SY5Y cells...
2016: Journal of Alzheimer's Disease: JAD
Laura Steadman, Joan S Grant, Lucinda J Graven
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C) levels, glucagon-like peptide-1 receptor agonists may be used. This article provides an overview of this class of agents and provides implications for home healthcare clinicians...
November 2015: Home Healthcare Now
Ju-Hee Oh, Ji Eun Lee, Yu Jeong Kim, Tack-Oon Oh, SungKyun Han, Eun Kyung Jeon, Kyungmin Shin, Dong-Hyun Kim, Chi Hye Park, Young-Joo Lee
Patients with type 2 diabetes mellitus have a high risk of cardiovascular disease mainly caused by dyslipidemia. Metformin and atorvastatin are preferentially used to treat type 2 diabetes mellitus and dyslipidemia, respectively. The aim of this study was to develop a once-a-day fixed-dose combination tablet containing metformin and atorvastatin. For this purpose, we designed gastroretentive bilayer tablets consisting of 500 mg metformin in a sustained release layer and 10 mg atorvastatin in an immediate release layer...
2016: Drug Development and Industrial Pharmacy
John B Buse, Ralph A DeFronzo, Julio Rosenstock, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman
OBJECTIVE: Delayed-release metformin (Met DR) is formulated to deliver the drug to the lower bowel to leverage the gut-based mechanisms of metformin action with lower plasma exposure. Met DR was assessed in two studies. Study 1 compared the bioavailability of single daily doses of Met DR to currently available immediate-release metformin (Met IR) and extended-release metformin (Met XR) in otherwise healthy volunteers. Study 2 assessed glycemic control in subjects with type 2 diabetes (T2DM) over 12 weeks...
February 2016: Diabetes Care
Cheng-Hung Lee, Shang-Hung Chang, Wei-Jan Chen, Kuo-Chun Hung, Yu-Huang Lin, Shih-Jung Liu, Ming-Jer Hsieh, Jong-Hwei S Pang, Jyuhn-Huarng Juang
This work developed nanofibrous drug-loaded collagen/poly-D-L-lactide-glycolide (PLGA) scaffold membranes that provided the sustained release of glucophage for the wounds associated with diabetes. PLGA, glucophage, and collagen were firstly dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol and were spun into nanofibrous membranes by electrospinning. High-performance liquid chromatography assay was used to characterize the in vivo and in vitro release rates of the pharmaceuticals from the membranes. High concentrations of glucophage were released for over three weeks from the nanofibrous membranes...
February 1, 2015: Journal of Colloid and Interface Science
E Bosman, A D Esterhuizen, F A Rodrigues, P J Becker, W A Hoffmann
Previous reports indicated that hyperinsulinaemic men may exhibit a higher percentage of poorly compacted DNA in their spermatozoa and less success in an IVF programme (Andrologia, 45, 2003, 18; Andrologia, 2014, doi: 10.1111/and.12227). The aim of this study was to investigate the effect of metformin (Glucophage®) and antioxidant treatment (StaminoGro®) on the semen parameters of hyperinsulinaemic men. Nineteen hyperinsulinaemic male patients were treated for 3 months with metformin alone (Group A), and fifteen patients used metformin in combination with the nutritional supplement (Group B)...
November 2015: Andrologia
Asma Irfan, Irfan Afzal Mughal, Samina Jalali
BACKGROUND: Research conducted over PCOS by various groups in the world indicated the effect of Metformin on PCOS. Previous studies suggest that Glucophage by reducing hyper-insulinemia is clinically useful in the treatment of polycystic ovary syndrome (PCOS). Our Objective was to observe the role of Glucophage in treating infertility of polycystic patients within three months in Group A and six months in Group B patients. Another aim was to assess the decrease in hyper-insulinemia and Leptin levels by Glucophage in our population...
January 2013: Journal of Ayub Medical College, Abbottabad: JAMC
Sahar Kamal Hegazy
Osteoporosis is the most important metabolic bone disease in patients with diabetes mellitus. Several studies have documented that metformin is osteogenic in vitro. In contrast, others showed no effect of metformin on the osteogenic differentiation of bone marrow-derived mesenchymal stem cells. Incretin hormones have received much attention because of their beneficial effects beyond glycemia, including on bone health. The study evaluated the anti-osteoporotic effect of metformin and sitagliptin in postmenopausal diabetic women...
March 2015: Journal of Bone and Mineral Metabolism
M A Momoh, F C Kenechukwu, A A Attama
The low encapsulation efficiency of conventional solid lipid microparticles (SLMs) especially for hydrophilic drugs has remained a challenge to drug formulation experts. This work seeks to address the issue of inefficient delivery of metformin hydrochloride (MTH), a potent hydrophilic oral antihyperglycemic agent, using novel SLMs based on solidified reverse micellar solutions (SRMS) prepared by melt-emulsification using a lipid derived from Capra hircus and Phospholipon® 90H. Characterization based on size, morphology, zeta potential, polydispersity index, encapsulation efficiency (EE%), loading capacity (LC) and time-resolved stability were carried out on the SLMs...
April 2013: Drug Delivery
Vijay V Upreti, Chi-Fung Keung, David W Boulton, Ming Chang, Li Li, Angela Tang, Bonnie C Hsiang, Donette Quamina-Edghill, Ernst U Frevert, Frank P Lacreta
BACKGROUND: As compared with individual tablets, saxagliptin/metformin immediate release (IR) fixed-dose combination (FDC) tablets offer the potential for increased convenience, compliance, and adherence for patients requiring combination therapy. OBJECTIVES: Two bioequivalence studies assessed the fed-state and the fasted-state bioequivalence of saxagliptin/metformin IR 2.5 mg/500 mg FDC (study 1) and saxagliptin/metformin IR 2.5 mg/1,000 mg FDC (study 2) relative to the same dosage strengths of the individual component tablets [saxagliptin (Onglyza™) and metformin IR (Glucophage(®))] administered concurrently...
May 2013: Clinical Drug Investigation
Ozgul Muneyyirci-Delale, Julie Kaplan, Ibrahim Joulak, Lianfu Yang, Hans Von Gizycki, Vijaya L Nacharaju
To assess the effect of glucophage, magnesium oxide and spironolactone in altering free fatty acids (FFAs), 36 PCOS women were randomly divided into three groups. Group 1 (n = 14) was treated with 500 mg glucophage po bid, group 2 (n = 10) was treated with 400 mg magnesium oxide po bid and group 3 (n = 12) was treated with 50 mg spironolactone po bid for 12 weeks. A glucose tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for insulin, glucose, FFA and aldosterone...
May 2013: Gynecological Endocrinology
Michał Krzysztof Kołodziejczyk, Justyna Kołodziejska, Marian Mikołaj Zgoda
AIM OF STUDY: Metformin hydrochloride after buformin and phenformin belongs to the group of biguanid derivatives used as oral anti-diabetic drugs. The object of the study is the technological analysis and the potential effect of biodegradable macromolecular polymers on the technological and therapeutic parameters of oral anti-diabetic medicinal products with metformin hydrochloride: Siofor, Formetic, Glucophage, Metformax in doses of 500mg and 1000mg and Glucophage XR in a dose of 500 mg of modified release...
2012: Polimery W Medycynie
Erin L St Onge, Shannon Miller, Elizabeth Clements
Used together, sitagliptin (Januvia) and metformin (Glucophage) help to improve glycemic levels in diabetic patients, suggesting a synergy between the agents. However, the cost of sitagliptin and the need for more data may restrict its use. More studies are needed to assess the effects of long-term sitagliptin and to determine its role in combination therapy.
December 2012: P & T: a Peer-reviewed Journal for Formulary Management
Joanna Suliburska, Paweł Bogdański, Barbara Chiniewicz
The aim of this study was to assess the influence of selected cardiovascular and antidiabetic drugs on in vitro pepsin activity. A total of 13 drugs were analyzed at one concentration (one tablet of drug in 50 mL of solution with deionized water). The enzyme activity was determined by the Folin method based on the reaction of tyrosine with the Folin reagent. It was found that ACE inhibitors (apo-perindox, prinvil, gopten) caused a significant decrease in the activity of pepsin, while indapen (a diuretic) and glucophage (an antidiabetic drug) increased the activity of this enzyme...
November 2012: Acta Poloniae Pharmaceutica
Iman Abdel Mohsen, Eman Elkattan, Hala Nabil, Sherif Khattab
PURPOSE: Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate. The aim of the study is to assess the effect of metformin on the endometrial vascular indices in anovulatory obese PCOS women using three-dimensional power Doppler sonography (3DPDUS). METHODS: A prospective study was set to determine the beneficial effects of metformin on PCOS patients...
June 2013: Journal of Clinical Ultrasound: JCU
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"